“EGFR Tyrosine Kinase Inhibitors Prolong Overall Survival in EGFR Mutated Non-Small-Cell Lung Cancer Patients With Postsurgical Recurrence ”. Journal of Cancer Research Updates, vol. 1, no. 1, Jan. 2012, pp.  102-107, https://doi.org/10.6000/1929-2279.2012.01.01.15.